Q-omics provides the consensus-scored PEX11A profile across patient tissues and cancer cell-line models. PEX11A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PEX11A is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PEX11A RNA expression shows 20,928 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where PEX11A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX11A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX11A survival associations across molecular data types. PEX11A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX11A RNA expression–survival associations across cancer types. High PEX11A expression shows unfavorable associations in HNSC, SCLC, CESC and ACC, but favorable associations in KIRC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PEX11A RNA expression.
This table summarizes PEX11A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PEX11A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX11A shows lower tumor expression in COAD, THCA, KICH, KIRP and LUAD and higher tumor expression in KIRC. The COAD box plot shows higher PEX11A RNA expression in normal versus tumor tissue (log2 FC = −1.254, t-test p < 0.001).
This table shows molecular features associated with PEX11A in patient tissues and cancer cell lines. In patient samples, PEX11A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX11A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
